Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Br J Nutr ; 122(3): 301-308, 2019 08 14.
Artigo em Inglês | MEDLINE | ID: mdl-31368422

RESUMO

We evaluated the effects of high-Ca fat-free milk v. low-Ca control diet on adiposity and on glycaemic control. Fourteen subjects with type 2 diabetes (aged 49·5 (sd 8·6) years, BMI 29·4 (sd 4·5) kg/m2, low habitual Ca consumption (<600 mg/d)) were included in this randomised, crossover clinical trial. Subjects participated in two 12-week experimental sessions (high-Ca fat-free milk (HC) or low-Ca control (LC)) separated by 8-week washout. Subjects daily consumed in the laboratory a breakfast shake containing 700 mg (HC) or 6·4 mg (LC) of Ca. Energy-restricted diets containing 800 mg of dietary Ca/d were prescribed. Dietary records data indicated the consumption of 1200 mg of Ca/d during HC and of 525 mg of Ca/d during LC. There was a greater reduction in body weight, body fat mass, waist circumference and waist:hip ratio after HC. Serum 25-hydoxyvitamin D and homeostatic model assessment-2 ß-cell function (HOMA2-%B) increased, and serum uric acid, parathormone (PTH) and glycated Hb (HbA1c) concentrations reduced after HC. In addition, changes from baseline in terms of serum uric acid, glucose, HbA1c and PTH concentrations were lower, and those of HOMA2-%B, serum Ca and 25-hydoxyvitamin D were higher after the HC than after LC. The consumption of approximately three servings of fat-free milk and 1200 mg of dietary Ca/d enhanced weight loss, improved body composition and promoted glycaemic control in subjects with type 2 diabetes and low habitual Ca consumption (<600 mg/d).


Assuntos
Cálcio da Dieta/administração & dosagem , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/dietoterapia , Hiperglicemia/sangue , Leite/química , Adulto , Animais , Composição Corporal , Índice de Massa Corporal , Peso Corporal , Estudos Cross-Over , Dieta , Método Duplo-Cego , Exercício Físico , Feminino , Homeostase , Humanos , Células Secretoras de Insulina/citologia , Masculino , Pessoa de Meia-Idade , Nutrientes/administração & dosagem , Hormônio Paratireóideo/sangue , Inquéritos e Questionários , Ácido Úrico/sangue , Vitamina D/análogos & derivados , Vitamina D/sangue , Circunferência da Cintura , Adulto Jovem
2.
Nutrients ; 11(7)2019 06 28.
Artigo em Inglês | MEDLINE | ID: mdl-31261732

RESUMO

Oral diabetes-specific nutritional supplements (ONS-D) induce favourable postprandial responses in subjects with type 2 diabetes (DM2), but they have not been correlated yet with incretin release and subjective appetite (SA). This randomised, double-blind, cross-over study compared postprandial effects of ONS-D with isomaltulose and sucromalt versus standard formula (ET) on glycaemic index (GI), insulin, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1) and SA in 16 individuals with DM2. After overnight fasting, subjects consumed a portion of supplements containing 25 g of carbohydrates or reference food. Blood samples were collected at baseline and at 30, 60, 90, 120, 150 and 180 min; and SA sensations were assessed by a visual analogue scale on separate days. Glycaemic index values were low for ONS-D and intermediate for ET (p < 0.001). The insulin area under the curve (AUC0-180 min) (p < 0.02) and GIP AUC (p < 0.02) were lower after ONS-D and higher GLP-1 AUC when compared with ET (p < 0.05). Subjective appetite AUC was greater after ET than ONS-D (p < 0.05). Interactions between hormones, hunger, fullness and GI were found, but not within the ratings of SA; isomaltulose and sucromalt may have influenced these factors.


Assuntos
Regulação do Apetite , Glicemia/metabolismo , Diabetes Mellitus Tipo 2/dietoterapia , Suplementos Nutricionais , Dissacarídeos/administração & dosagem , Frutose/administração & dosagem , Índice Glicêmico , Isomaltose/administração & dosagem , Hormônios Peptídicos/sangue , Administração Oral , Biomarcadores/sangue , Estudos Cross-Over , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/fisiopatologia , Diabetes Mellitus Tipo 2/psicologia , Dissacarídeos/efeitos adversos , Método Duplo-Cego , Feminino , Frutose/efeitos adversos , Polipeptídeo Inibidor Gástrico/sangue , Peptídeo 1 Semelhante ao Glucagon/sangue , Humanos , Insulina/sangue , Isomaltose/efeitos adversos , Masculino , Pessoa de Meia-Idade , Fatores de Tempo , Resultado do Tratamento
3.
Biomed Res Int ; 2018: 4806534, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29511682

RESUMO

Noncaloric sweeteners (NCS) are food additives used to provide sweetness without adding calories. Their consumption has become more widespread around the world in all age groups, including children. The aim of this study is to show the state of the art about the intake of noncaloric sweeteners in children, as well as their benefits and consumption risk. Scientific searchers were used (PUBMED, Scopus, and Scielo) to analyze articles that included keywords (noncaloric sweeteners/saccharin/cyclamate/acesulfame potassium/aspartame/sucralose/stevia/children) in English, Spanish, and Portuguese. Authors conclude that it is imperative that health professionals judiciously and individually evaluate the overall benefits and risks of NCS use in consumers before recommending their use. Different subgroups of the population incorporate products containing NCS in their diet with different objectives, which should be considered when recommending a diet plan for the consumer. In childhood, in earlier age groups, this type of additives should be used as a dietary alternative when other forms of prevention in obesity are not sufficient.


Assuntos
Ingestão de Energia , Aditivos Alimentares/uso terapêutico , Obesidade/dietoterapia , Edulcorantes/uso terapêutico , Aspartame/efeitos adversos , Aspartame/uso terapêutico , Criança , Ciclamatos/efeitos adversos , Ciclamatos/uso terapêutico , Aditivos Alimentares/efeitos adversos , Humanos , Obesidade/epidemiologia , Obesidade/prevenção & controle , Medição de Risco , Sacarina/efeitos adversos , Sacarina/uso terapêutico , Stevia/química , Sacarose/efeitos adversos , Sacarose/análogos & derivados , Sacarose/uso terapêutico , Edulcorantes/administração & dosagem , Tiazinas/efeitos adversos , Tiazinas/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...